A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Required: ALK wild-type

Required: EGFR wild-type

Required: ROS1 wild-type

Cannot have received: systemic therapy

Any prior systemic therapy received for advanced or mNSCLC (metastatic non-small cell lung cancer).

Cannot have received: anti-TIGIT therapy

Any prior exposure to an anti-TIGIT (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms.

Cannot have received: anti-PD-1 therapy

Any prior treatment with an anti-PD-1 (programmed cell death protein 1) or anti-PD-L1 (anti-programmed death-ligand 1) agent.